Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 124 results found. Search for [ COVID-19 vaccine Gamaleya ]

Results 20 to 40 of 124
BusinessToday.In
April 6, 2021
Share of the pharma firm rose 19.99% to Rs 220.85 against previous close of Rs 184.40 on BSE. The stock opened with a gain of 15.68% at Rs 212.90


Rashi Bisaria
New Delhi, April 6, 2021
COVID-19 vaccination: Uddhav Thackeray asks PM Modi to reduce eligible age to 25 yrsMaharashtra Chief Minister Uddhav Thackeray has written a letter to Prime Minister Narendra Modi asking to reduce the age for getting COVID-19 vaccination to 25 years. Saying that the second wave of the coronavirus is much stronger than the first wave in the state, Thackeray said Maharashtra is taking up vaccination at a rapid pace and is the number 1 state in the country in terms of COVID-19 vaccine doses adm...


BusinessToday.In
April 5, 2021
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.


BusinessToday.In
March 19, 2021
Stelis and the RDIF plan to start supplying the vaccine doses in the third quarter of this year, said Strides Pharma. It is yet to be ascertained which countries the doses would go to


BusinessToday.In
March 16, 2021
Share of Gland Pharma touched an all-time high of Rs 2,784.45, rising 9.54% against previous close of Rs 2,541 on BSE


BusinessToday.In
March 16, 2021
COVID-19 vaccine: Gland Pharma said that the production of Sputnik V is expected to commence from third quarter of 2021 for estimated delivery starting from fourth quarter of 2021


PB Jayakumar
March 3, 2021
So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy


BusinessToday.In
February 20, 2021
Russia has already approved two COVID-19 vaccines, Sputnik V and EpiVacCorona, which were also granted approval before seeing any late-stage trial results


BusinessToday.In
February 19, 2021
As part of the review process, Dr Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 21st February 2021.


BusinessToday.In
February 15, 2021
Earlier, Dr Reddy's had said it expects to roll out Sputnik V vaccine in India in March via Emergency Use Authorisation (EUA) after the completion of Phase 3 trials.


BusinessToday.In
February 3, 2021
Earlier, The Lancet had stated that Russia's experimental COVID-19 vaccine Sputnik V is 91.6 per cent affective against coronavirus infection. These results are based on Phase 3 trials of the vaccine in which 20,000 people had participated


BusinessToday.In
February 3, 2021
The pharma stock touched an intraday high of Rs 4,759.1 rising 6.13% against previous close of Rs 4,484.25 on BSE


BusinessToday.In
January 30, 2021
Sputnik V is undergoing Phase-3 trials in India currently which is expected to be completed by February


PTI
January 16, 2021
Speaking at the 25th Wharton India Economic Forum, he said the Indian pharma industry ensured the continuity of supplies


BusinessToday.In
January 13, 2021
Coronavirus vaccination drive: Serum Institute will provide the coronavirus vaccine at Rs 200 per dose, while Bharat Biotech would provide Covaxin at Rs 206 per dose to the government


BusinessToday.In
January 12, 2021
Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia's Sputnik-V vaccine


Rajeev Dubey | Vivek Punj
January 11, 2021
Full authorisation-better known as \"full pre-qualification\"-is a pre-requisite to sell the vaccine in the open market or for mass immunisation of healthy individuals who are not frontline workers


PTI
January 6, 2021
(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing


BusinessToday.In
December 29, 2020
Russia's Gamaleya centre had earlier invited researchers from the University of Oxford to add a component of its vaccine to a component of AstraZeneca's, informed Alexander Gintsburg, Gamaleya centre's head


BusinessToday.In
December 19, 2020
The COVID-19 vaccine in India will be first offered to healthcare workers, frontline workers and persons above 50 years of age. Depending on the disease epidemiology and vaccine's availability, the remaining population will be vaccinated later on


PAGES 2 OF 7  12345